成纤维细胞生长因子21对缺氧复氧心肌细胞的保护作用及机制研究

【摘要】 目的 探讨成纤维细胞生长因子21（FGF21）对缺氧复氧（H/R）心肌细胞的保护作用及对PI3K/AKT通路的影响。方法 重组腺病毒载体Ad FGF21诱导原代心肌细胞过表达FGF21。腺病毒转染心肌细胞后构建H/R损伤模型（3h缺氧联合3h复氧）。实验分为对照组（Con组）、H/R组、H/R+Ad GFP组、H/R+Ad FGF21组4组。心肌细胞存活率评估细胞损伤程度;SOD/MDA检测联合DHE荧光染色评估氧化应激反应（ROS）;流式细胞术评估细胞凋亡;Western blot检测相关蛋白水平。在机制探讨实验中给予PI3K/AKT抑制剂（LY294002）进行干预。结果 与Con组相比,H/R损伤后FGF21蛋白表达显著下调,并伴随心肌细胞活性降低、ROS与凋亡反应激活。腺病毒介导的心肌细胞过表达FGF21能够明显抑制H/R损伤,表现为细胞活力、ROS与凋亡反应均有不同程度改善。FGF21心肌细胞过表达能够增加PI3K/AKT磷酸化水平,而抑制PI3K/AKT通路后FGF21过表达介导的细胞保护功能被逆转。结论 FGF21主要通过PI3K/AKT依赖性途径改善心肌细胞H/R损伤。     

Evaluation of the osseointegration of dental implants coated with calcium carbonate:an animal study

In an attempt to overcome the limitations of titanium in dental and orthopaedic clinical applications, a new method has been developed to prepare calcium carbonate coatings on sandblasted and acid-etched (SA) titanium implants. The purpose of this study was to investigate the effect of calcium carbonate-SA (CC-SA) implants on osseointegration in vivo. The surfaces of SA and CC-SA implants were characterised for surface morphology and surface chemistry. Subsequently, these two kinds of implants were implanted in the femoral condyles of rabbits. The implants were retrieved and prepared for histological and histomorphometric evaluation 1, 2, 4, 8 and 12 weeks after implantation. Significantly higher values of bone-to-implant contact of the entire implant except the gap area (BIC_ALL) and the bone-to-implant contact of the gap area (BIC_GAP) were found in animals with the CC-SA implants than in those with the SA implants at 4 weeks. Higher values of total gap bone were found in those with the CC-SA implants than in those with the SA implants at 1, 2 and 4 weeks. In conclusion, the current findings demonstrate that the calcium carbonate coating can improve and accelerate the early ingrowth of bone and osseointegration at the early healing phase. This may reduce clinical healing times and thus improve implant success rates.     

Risk factors for and predictive nomogram of overall survival in adult patients with craniopharyngiomas: A SEER population-based study

Studies with relatively large sample size as well as long-term follow-up focusing on adult craniopharyngioma (CP) patients are still lacking. We attempted to identify independent prognostic factors and establish a nomogram model to estimate survival rates for adult CP patients.The Surveillance, Epidemiology, and End Results database was used to obtain data on patients with CP. Univariable and multivariable Cox analyses were utilized to identify the prognostic factors of adult CP patients. A survival prediction model was constructed and its predictive performance was also assessed.A total of 991 patients (695 in training group and 296 in validation group) were eligible for final inclusion. Multivariate Cox analysis presented that age at diagnosis, marital status, race, tumor size, and surgery type were statistically significant prognostic factors for overall survival (all P < .05). A graphical predicting nomogram model was developed to calculate the predicted patients’ survival probabilities at 1, 2, 5, and 10 years. The concordance indexes were 0.708 ± 0.019 and 0.750 ± 0.025 for the training and validation samples, respectively, demonstrating favorable discrimination abilities. Similarly, the time-dependent area under curve also showed overall satisfactory discrimination ability. Favorable consistencies between the predicted and actual survival were presented according to the calibration curves.An easy-to-use nomogram, being proven to be with reliable discrimination ability and accuracy, was established to help predict overall survival for adult patients with CP using the identified significant prognostic factors.     

LncRNA SNHG1 promotes renal cell carcinoma progression through regulation of HMGA2 via sponging miR‐103a

BackgroundLong noncoding RNAs (LncRNAs) plays a vital role in tumorigenesis and development. The molecular mechanism of SNHG1 in renal cell carcinoma (RCC) has not been illustrated. The aim of this research was to explore the expression and function of LncRNA SNHG1 in RCC.Material and MethodsThe expression of SNHG1 in clinical tissues and RCC cell lines was detected. Luciferase reporter assay was performed to verify the correlation between SNHG1, miR‐103a, and HMGA2. CCK‐8 assay was performed to examine cell viability. Cell apoptosis was analyzed using flow cytometry. Cell invasion capacity was determined by Transwell assays. The protein level of HMGA2 was analyzed by Western blotting.ResultsThe expression of SNHG1 markedly increased in RCC tissues and cell lines. Subsequent studies identified SNHG1 as a miRNA sponge for miR‐103a. In addition, SNHG1 knockdown and miR‐103a overexpression significantly inhibited progression of RCC. miR‐103a also regulated HMGA2 levels.ConclusionOur findings showed that SNHG1 was upregulated in RCC cells and tissues. SNHG1 promoted the malignant characteristics of RCC cells. Its regulatory effect may be regulation of HMGA2 by sponging miR‐103a. Therefore, Our study facilitates the understanding of SNHG1 function in RCC.     

1例新型冠状病毒肺炎中西药联合治疗临床实践

目的 探讨新型冠状病毒肺炎的中西药联合治疗方案。方法 分析湖北省黄石市首例治愈出院的新型冠状病毒肺炎患者的药物治疗方案及疗效。结果 中西药联合治疗明显缓解了该患者的发热、咳嗽、乏力等临床症状,肺部CT检查显示感染范围明显缩小,病毒RNA检测转阴,临床疗效较好。结论 中西药联合治疗方案对该例新型冠状病毒肺炎患者的治愈具有积极作用。     

2015-2017年黄石市妇幼保健院住院患者感染MRSA的用药调查

目的 了解黄石市妇幼保健院住院患者感染耐甲氧西林金黄色葡萄球菌（MRSA）的用药情况。方法 选取2015-2017年该院院内感染MRSA的住院病历410份,对标本来源、抗菌药名称、用法用量、疗程、联合用药及特殊级抗菌药物临床应用管理等进行调查,计算抗菌药物用药频度（DDDs）和药物利用度指数（DUI）,并对不适宜用药进行总结。结果 410株MRSA标本主要来自于痰液（51.46%）、脓性分泌物（22.44%）和血液（12.44%）。410份病历中,共涉及6种抗菌药,其中替考拉宁使用最多（32.81%）,其次为万古霉素（25.79%）和利奈唑胺（23.08%）;替考拉宁的DDDs最大（1 512.35）,其次为利奈唑胺（922.83）和万古霉素（907.20）,所有药物的DUI ≤ 1.0;用药不适宜病历57份（13.90%）,主要为用法用量不适宜（25份,43.86%）和溶媒不适宜（16份,28.07%）;所有特殊级抗菌药物均未越级使用,但只有38份（9.27%）经专家会诊后使用。结论 万古霉素、替考拉宁和利奈唑胺是该院治疗MRSA感染的主要药物,且临床使用较好,不存在滥用倾向,但也有必要进一步规范合理用药,延缓细菌耐药。     

浅谈“面口合谷收”的理论基础与临床应用

"面口合谷收"是医疗实践过程中对合谷治疗口面部疾病功效的高度总结。笔者查阅相关文献,从中医经络辨证角度出发,结合现代医学对其生理机制的研究,探讨支撑其证治规律的理论实质;同时对临床运用合谷穴治疗口面部疾病的报道进行举案归纳,浅析"面口合谷收"的理论基础与临床运用。     

妊娠期糖尿病孕妇外周血胎儿游离DNA检测及其临床意义

目的通过检测妊娠期糖尿病孕妇外周血胎儿游离DNA浓度变化,分析基因表达水平是否正常,为诊断和阐明妊娠期糖尿病及其遗传效应提供理论依据。方法用血浆基因组DNA磁珠法抽提12~25周孕早中期孕妇外周血中胎儿游离DNA,妊娠期糖尿病组和健康对照组各15例,通过高通量测序检测孕妇胎儿染色体基因拷贝数及评估其风险值。结果与健康对照组比较,妊娠期糖尿病组的孕妇胎儿游离DNA文库浓度差异无统计学意义(P>0.05),染色体基因拷贝数无显著变化,但个别存在18号染色体基因微重复,可能与妊娠期糖尿病基因表达异常相关。结论对妊娠期糖尿病孕妇外周血胎儿游离DNA检测,将有助于进一步研究妊娠期糖尿病形成的分子机制及其临床诊断。     

阿托伐他汀联合曲美他嗪对冠心病患者的疗效及血脂水平的临床评价

目的 研究冠心病患者治疗中阿托伐他汀联合曲美他嗪对心绞痛改善情况和血脂水平的影响。方法 选取2015年11月-2017年12月就诊的149例冠心病患者作为研究对象,按随机数字表法分为对照组（n=71）和观察组（n=78）。对照组患者口服曲美他嗪20 mg、3次/d,观察组在对照组基础上口服阿托伐他汀20 mg、1次/d,8 d为1个疗程。对比两组患者平板运动试验、丙二醛（MDA）和超氧化物歧化酶（SOD）水平、血脂水平和临床疗效。结果 治疗后研究组的诱发心绞痛发作时间和运动持续时间明显高于对照组,心电图ST段下移1 mm时间明显低于对照组（P<0.05）;两组治疗后ST段下移1 mm时间、诱发心绞痛发作时间和运动持续时间等平板运动试验项目均明显高于同组治疗前（P<0.05）。两组治疗后MDA和SOD水平与各自治疗前对比均有统计学差异（P<0.05）;治疗后观察组患者MDA水平明显低于对照组,SOD水平明显高于对照组（P<0.05）。两组治疗后血脂水平与同组治疗前比较均有统计学差异,且观察组患者血脂水平明显低于对照组（P<0.05）。对照组患者总有效率为67.61%,观察组患者总有效率为93.59%,两组比较有统计学差异（P<0.05）。结论 在冠心病治疗中,阿托伐他汀联合曲美他嗪可明显抑制氧化应激损伤,改善心电图平板试验、改善血脂代谢,提高疗效,值得临床推广。     

羟考酮联合加巴喷丁治疗中重度癌性疼痛的Meta-分析

目的 系统评价羟考酮联合加巴喷丁应用中重度癌性疼痛的有效性和安全性。方法 检索PubMed、Medline、中国期刊全文数据库（CNKI）、维普中文科技期刊全文数据库（VIP）、中国生物医学全文数据库（CBM）和万方数据库中关于羟考酮联合加巴喷丁治疗癌性疼痛的随机对照研究,检索时限为2000年1月至2017年8月。由2名研究者独立提取数据、评价质量,并交叉核对。采用RevMan 5.2软件进行Meta-分析。结果 共纳入10项研究,687例患者。Meta-分析结果显示：羟考酮联合加巴喷丁较羟考酮单用能显著提高疼痛缓解率[OR=3.85,95%CI（2.25~6.60）,P<0.000 01]和降低疼痛评分[MD=-0.83,95%CI（-0.95~-0.70）,P<0.000 01];能显著减少羟考酮的剂量[MD=-17.10,95%CI（-20.16~-14.04）,P<0.000 01];能显著减少便秘[OR=0.58,95%CI（0.42,0.82）,P=0.002]和恶心呕吐[OR=0.55,95%CI（0.37,0.82）,P=0.003]的发生率;能显著提高细胞免疫（CD4、CD8、CD4/CD8）和体液免疫（IgA、IgG、IgM）水平,差异均有统计学意义（P<0.01）。结论 羟考酮联合加巴喷丁能显著提高疼痛缓解率、降低疼痛评分,减少羟考酮平均日剂量,增强免疫功能,减少便秘和恶心呕吐等不良反应发生率,但两组头痛头晕、嗜睡和尿潴留的发生率无统计学差异。